Superluminal Medicines secured a $60 million Series B to advance its obesity program into first-in-human testing. The financing is designed to support Phase 1 development of next-generation small-molecule therapies targeting challenging GPCR-related endocrine and cardiometabolic pathways. The company’s approach integrates AI/machine learning, protein dynamics, and structural biology to improve the odds of success in GPCR target space, where compound optimization often depends on nuanced binding and functional outcomes. With obesity demand still driving capital flow, the round signals continued investor willingness to back modality shifts and earlier clinical transitions.